Are Investor Tempted to Buy Stocks Watch Now ( HEB, FOLD, ZLTQ, HOLL )

Los Angelas, CA -- (SBWIRE) -- 10/10/2012 -- Shares of Hemispherx BioPha (AMEX:HEB) are trading at $0.70 and is -8.92% from its 50-day Moving Average price of $0.7686 and +60.25% from its 200-day Moving Average price of $0.4368. The average trading volume is 2238900 shares and its market capitalization is $95.4M. Hemispherx BioPharma Inc (NYSEAMEX: HEB) decreased 11.01% and closed at $0.712 on a traded volume of 4.44 million shares. The Company has filed with ANMAT for the use of its natural-source Alferon N Injection patients with chronic hepatitis C who have become refractory to recombinant interferon as a result of the appearance of neutralizing antibodies against recombinant interferon. ANMAT is the agency responsible for the national regulation of drugs, foods and medical technology inArgentina.

Can HEB Continue To Move Higher? Find Out Here

Amicus Therapeuti (NGM:FOLD) is +0.38 - +7.35% from the previous close of $5.17. It traded between $5.45 - 6.15 with total traded volume of 1916199 shares. Keep a close eye on FOLD, as the stock has been showing unusual moves over the past weeks. At Current market price, FOLD has recovered +164.29% from its 52-week Low of 2.10 and has Pulled back -23.87% from its 52-week high of 7.29. Amicus Therapeutics, Inc. (FOLD) is a company with the potential to attract a good deal of philanthropist investors.Amicus is utilizing a new technology in the development of treatments for genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity.In its Fabry program, the company is investigating the use of AT1001 to bind to destabilized ?-galactosidase A enzyme (?-GAL) and thereby restore its intended biological function.Fabry disease is a rare X-linked (inherited) lysosomal storage disease, which can cause a wide range of systemic symptoms. It is a form of sphingolipidosis, as it involves dysfunctional metabolism of sphingolipids. There has been historic difficulty in finding successful treatments for rare genetic diseases such as Fabry's. If Amicus can show successful phase III data here, it could very well be like a "Kodak" moment in medicine's war against genetic diseases -- groundbreaking.

Should Investors Hold Their Position In FOLD ? Find Out Here

Aesthetics (NasdaqNM:ZLTQ) reported EPS of -1.197. For the Current Fiscal year, the company is expected to report EPS of -0.86. For the Next Quarter and Next Year, the company is expected to report EPS of -0.11 and -0.49 respectively. At Current Market Price, ZLTQ is in distance of +7.00% from its 50-day Moving Average price of $5.7477 and +13.33% from its 200-day Moving Average price of $5.4264. ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it filed a lawsuit in the United States District Court for the Middle District of Florida, Tampa Division, against Marco Hallerbach, MD, and Dr. Hallerbach & Associates, Inc., for false advertising, false designation of origin, unfair competition, trademark infringement, and unfair and deceptive trade practices. In addition, ZELTIQ simultaneously filed a motion requesting a preliminary injunction to cease Dr. Hallerbach's misleading advertising and prevent him from further use of ZELTIQ's trademarks.

What’s Going With ZLTQ? Find Out Here:

Shares of Hollywood Media C (NGM:HOLL) are trading at $1.40 and is +6.85% from its 50-day Moving Average price of $1.3103 and +14.57% from its 200-day Moving Average price of $1.2219. The average trading volume is 17985 shares and its market capitalization is $32.5M. Hollywood Media Corporation(NASDAQ:HOLL) shares climbed 15.20% to $1.44 in the early hour. On October 1, 2012, Hollywood Media received the first $7,000,000 earnout payment from Key Brand Entertainment pursuant to that certain Stock Purchase Agreement between Hollywood Media and Key Brand dated as of December 22, 2009, as amended relating to the sale of the Theatre Direct business.

Don’t forget To Apply for Trend Analysis Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com